SNAP-8

SNAP-8 (acetyl octapeptide-3) is a topical cosmetic peptide marketed for softening expression lines, like forehead and crow's-feet lines. It's an eight-amino-acid relative of the better-known peptide Argireline — both are modeled on a piece of SNAP-25, a protein involved in the signals that make facial muscles contract, with the idea being to gently reduce that signaling at the skin surface. It is a cosmetic ingredient, not Botox, not an FDA-approved drug, and not injected.

SNAP-8 is a cosmetic "anti-wrinkle" peptide, but no published trial isolates it on its own — where it appears in studies it is one ingredient among several, so its individual contribution can't be separated out. The stand-alone evidence is instead for its close sibling Argireline (acetyl hexapeptide-8), which works by the same mechanism: in a randomized, placebo-controlled study, topical Argireline twice daily for 4 weeks significantly reduced peri-orbital wrinkles versus placebo. SNAP-8 is marketed as a longer version of the same idea, but that specific claim rests on manufacturer data, not independent trials.

Not a drug. SNAP-8 (acetyl octapeptide-3) is used as a topical cosmetic ingredient, not an FDA-approved medicine — cosmetic ingredients are not pre-approved by the FDA the way drugs are, and no SNAP-8 drug product exists. It is a "neurotransmitter-inhibiting" cosmetic peptide applied to skin (serums/creams), not injected, and is not botulinum toxin. WADA: not listed on the Prohibited List (topical cosmetic). Not DEA-scheduled.

SNAP-8 is a topical cosmetic and is generally considered low-risk at cosmetic concentrations. It is not botulinum toxin (Botox) and does not work nearly as strongly; it is also not injected. As with any topical, irritation or allergy is possible, so patch-testing is sensible. It is a cosmetic ingredient, not a medical treatment, and is not on the WADA Prohibited List. VialWise is a research and educational reference, not medical advice.

⚠️ For research and educational purposes only. SNAP-8 (acetyl octapeptide-3) is a topical cosmetic ingredient, not an FDA-approved drug. It is not botulinum toxin (Botox) and is not a medical treatment. Information here is informational, not medical advice.

⚠️ This is a topical, not an injectable. SNAP-8 is formulated into serums/creams and applied to the skin — it is not reconstituted for injection like the research peptides elsewhere in this library. The reconstitution guidance below is for topical formulation, not injection.

⚠️ The evidence is for Argireline, not SNAP-8 specifically. No published trial isolates the effect of SNAP-8 (an octapeptide) on its own — where it appears in peer-reviewed clinical studies, it is one active among several in a combined formulation, so standalone SNAP-8 efficacy is unproven. The clinical and mechanistic data below are for its close sibling Argireline (acetyl hexapeptide-8), which shares the same SNAP-25/SNARE mechanism.[¹][²][³] SNAP-8's marketed advantage as a "longer, stronger" version rests on manufacturer data, not independent studies — treat that claim cautiously.

SNAP-8 is the common name for acetyl octapeptide-3, a topical cosmetic peptide marketed to soften expression lines. It is a close relative of Argireline (acetyl hexapeptide-8) — both are short peptides patterned on the N-terminal end of SNAP-25, a protein in the SNARE complex that nerve endings use to release the signal (acetylcholine) that makes muscles contract.[²][³] In the cosmeceutical-peptide classification, both belong to the "neurotransmitter-inhibiting" category: the topical idea is to gently reduce the muscle-contraction signaling that deepens dynamic expression lines. This is a far weaker, surface-level effect than injectable botulinum toxin, with which it is sometimes (misleadingly) compared.

Mechanism (as described for the Argireline family). According to PubMed, Argireline is described as inhibiting vesicle docking by preventing formation of the ternary SNARE complex and by interfering with catecholamine release — reducing, at the skin level, the neuromuscular signaling that contributes to expression wrinkles.[¹][²] SNAP-8, as an octapeptide extension of the same SNAP-25-derived motif, is marketed to act by the same mechanism.

The evidence gap (stated plainly). No published trial isolates SNAP-8 itself. The peer-reviewed clinical studies that contain acetyl octapeptide-3 are multi-ingredient formulations (microneedle patches combining it with other actives), so its individual contribution cannot be separated — standalone SNAP-8 efficacy remains unproven. The usable evidence is for Argireline: - A randomized, placebo-controlled study in 60 Chinese subjects applied topical Argireline (or placebo) to peri-orbital wrinkles twice daily for 4 weeks. By subjective evaluation, total anti-wrinkle efficacy was ~48.9% in the Argireline group vs 0% in placebo, and objective roughness parameters decreased significantly in the Argireline group only.[¹] - Formulation/mechanism reviews describe Argireline's SNAP-25 patterning and stability in cosmetic bases.[²] - Dermatology reviews classify these as "neurotransmitter" cosmeceutical peptides with plausible but still-limited evidence.[³]

SNAP-8's claimed advantage (a longer peptide said to be more effective) comes from supplier/manufacturer data, not independent trials — so the honest framing is: the *mechanism* has some clinical support via Argireline, but SNAP-8-specific efficacy is unproven.

Evidence quality. Limited. Real cosmetic-trial data exist for the sibling compound (Argireline); SNAP-8 rides on that mechanism plus manufacturer claims. Effects, even for Argireline, are modest and cosmetic, not medical.

Regulatory status (US). SNAP-8 is not a drug — it is a topical cosmetic ingredient, not pre-approved by the FDA. It is not botulinum toxin. Not DEA-scheduled.

Regulatory status (sport — WADA). Not listed on the WADA Prohibited List (topical cosmetic).

Common cosmetic interests. Topical "expression-line" serums (forehead lines, crow's feet), often marketed as a needle-free alternative idea to injectables — a comparison that overstates the strength of any topical peptide.

Commonly reported

• Local irritation, redness, or itching at the application site
• Contact allergy in sensitive individuals
• It is not botulinum toxin and does not cause muscle paralysis; any effect is a mild, surface-level cosmetic one.
• No systemic concern is expected from normal topical use.
• Do not inject this — it is a topical ingredient.

Not a medical or anti-wrinkle "treatment," and not Botox — SNAP-8 is a cosmetic ingredient with modest, unproven-for-SNAP-8 effects; it does not replace medical or injectable options.

Known allergy/sensitivity to the peptide or formulation — avoid

Broken or compromised skin — avoid applying cosmetic peptides to open or irritated skin

Pregnancy and lactation — topical cosmetic use is generally considered low-risk, but consult a clinician if unsure

Do not inject — this is a topical ingredient with no injection safety data

Regulatory note (US): Cosmetic ingredient, not an FDA-approved drug; not botulinum toxin. Not DEA-scheduled.

Regulatory note (sport): Not on the WADA Prohibited List.

SNAP-25

A protein that helps nerve endings release the chemical signal that makes muscles contract. SNAP-8 and Argireline are modeled on a piece of it.

Neurotransmitter-inhibiting peptide

A cosmeceutical-peptide category meant to gently reduce the muscle- contraction signaling that deepens expression lines — a topical idea, far weaker than injectable Botox.

Argireline

Acetyl hexapeptide-8, the more-studied sibling of SNAP-8. Most of the real evidence is for Argireline, not SNAP-8.

Expression lines

Wrinkles caused by repeated facial movements (forehead lines, crow's feet), as opposed to lines from sun damage or volume loss.

Topical

Applied to the skin surface (a serum or cream), not injected.

1. Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. (2013). The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. American Journal of Clinical Dermatology, 14(2):147–153.(PMID 23417317)
2. Ruiz MA, Clares B, Morales ME, Cazalla S, Gallardo V. (2007). Preparation and stability of cosmetic formulations with an anti-aging peptide. Journal of Cosmetic Science, 58(2):157–171.(PMID 17520155)
3. Lupo MP, Cole AL. (2007). Cosmeceutical peptides. Dermatologic Therapy, 20(5):343–349.(PMID 18045359)

• AHK-Cu — same mechanism class
• Matrixyl — same mechanism class
• Afamelanotide — shared research area
• GHK-Cu — shared research area
• GLOW — shared research area
• KLOW — shared research area